Home / Psoriasis (page 3)


Here you will find the latest clinical research on psoriasis.

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

  Purpose This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream. Condition Intervention Phase Psoriasis Vulgaris Drug: MC2-01 cream Drug: Cal/BDP combination Drug: Cream vehicle Phase 3 Study Type: Interventional Study Design: Allocation: RandomizedIntervention …

Read More »

Analysis of Treatment Goal Alignment between Japanese Psoriasis Patients and their paired Treating Physicians

Japanese Psoriasis

Abstract Background Appropriate goal-oriented treatment strategies are important for optimal treatment outcomes and may prevent under-treatment. As treatment goals vary by patient, a study to examine treatment goals is more meaningful when patients and their physicians are paired. There has not been any study that examines alignment between paired psoriasis …

Read More »

Longer Psoriasis Duration May Mean Higher CVD Risk


Duration of mild or moderate psoriasis had an influence on the risk of major acute coronary events (MACE) over time, a cohort and population study together showed. Based on imaging study results and observational registry data, investigators found that for each additional year of disease duration, there was a 1% …

Read More »

Risk of uncommon cancers in patients with psoriasis

psoriasis cancer risk

Abstract Background Cancer-associated mortality is increased in psoriasis. However, little is known about the risk of less common cancers. Objective We aimed to evaluate the risk of less common cancers in patients with psoriasis compared to persons without psoriasis using a nationwide cohort study. Methods Between January 1st 2008 and December …

Read More »

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care


Abstract Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of a defined minimal length were required and use of concomitant psoriasis medication was prohibited. There is therefore …

Read More »